Clinically Tested Red Yeast Rice – Cholesterol Control Without Statins
Clinically Tested Red Yeast Rice – Cholesterol Control Without Statins
Why Choose ANKASCIN® 568?

As regulatory authorities like EFSA tighten restrictions on monacolin K even at low doses, traditional red yeast rice products are facing increased scrutiny. This is the time that you can shine your product in the next few years!

ANKASCIN® 568 is your future-proof solution—no monacolin K, no statin-like side effects, and fully compliant with both current and upcoming regulations.

Comparison Between ANKASCIN® 568 and Traditional Red Yeast Rice

Comparison Between Ankascin 568 and Traditional Red Yeast Rice

Ankascin 568 Traditional Red Yeast Rice
Active compounds Monascin and Ankaflavin Monacolin K
Safety Free of Monacolin K diabetes, muscle soreness, and liver and kidney damage
Clinically Proven 5 Clinical Trial Publications Unknown
Fermentation method Automated Solid state fermentation Small-scale fermentation
Patent 20+ Global Patents Unknown
SCI Publication 140 SCI Publications Unknown
Mechanism Monascin and ankaflavin help reduce cholesterol levels by inhibiting its absorption and enhancing its breakdown in the body. Monacolin K helps to inhibit the synthesis of cholesterol by blocking the action of HMG-CoA reductase enzyme in the liver.
Extra Benefits Maintains Healthy TC and LDL
Maintains Healthy Triglyceride and HDL
Maintains Healthy Blood Sugar
Maintains Healthy Blood Pressure
Maintains Healthy TC and LDL
Regulatory Status Apply for EU and USA Regulation EU: Restrict Monacolin K Content (Less than 3mg) USA: 0 mg Canada: 1 mg
The ANKASCIN® 568 Advantage-Clinically Proven

Clinical Study: Maintains Healthy Cholesterol Level

In a randomized, double-blind clinical study of the effects of ANKASCIN® 568, serum cholesterol was reduced by 11.9% after four weeks of supplementation with ANKASCIN® 568 and LDL-C was reduced by 19%. *Liu SF, Wang YR, Shen YC, et al. A randomized, double-blind clinical study of the effects of Ankascin 568 plus on blood lipid regulation. J Food Drug Anal. 2018;26(1):393-400.

Clinical Study: Effect of ANKASCIN® 568 on blood glucose subjects in metabolic syndrome

In a randomized, double-blind human clinical study, fasting blood glucose was significantly reduced by 8.5% after just 6 weeks of taking ANKASCIN® 568 and by 9.3% after 12 weeks of use.⁴ *Wang YR, Liu SF, Shen YC, et al. A randomized, double-blind clinical study to determine the effect of ANKASCIN 568 plus on blood glucose regulation. J Food Drug Anal. 2017;25(2):409-416.

Clinical Study: Effect of ANKASCIN® 568 on blood pressure

In a clinical trial, subjects in the test group had a significantly reduced systolic (SBP) and diastolic blood pressure (DBP) following 4 weeks of administration, and results were maintained until the end of the 8-week period.  *Chen CL, Tseng JH, Pan TM, Hsiao SH. A Randomized, Double-Blind Clinical Study on Blood Pressure Reduction and Blood Lipid Profile Amelioration on Treatment with Ankascin 568. Chin J Physiol. 2017 Jun 30;60(3):158-165.

Safety Evidence

#1 No Monacolin K
- Comply with EU and US Regulatory Status

“Ankascin 568-P corresponds to the traditional preparation of red yeast rice. Therefore, this preparation is compliant with the current European Regulations, since the product, in addition to respecting the traditional manufacturing process of classical red yeast rice preparations, does not provide any monacolin. Therefore, Ankascin 568-P can be used in the European market.”

 

FoodChain ID Compliance Report

“Your notification states that the new dietary ingredient is a red yeast fermented product extracted from Monascus purpureus that you call “ANKASCIN 568-R.” According to your amended notification, the conditions of use are: “For adults, take 0.11 g (per capsule) once or twice a day, with water after a meal. Take 0.1 lg (per capsule) once or twice a day, with water aftera  meal. The product is safe for long-term consumption.”

 

US FDA Notification Report

No Monacolin K

FDA NDI

No Side Effect

No Monacolin K

FDA NDI

No Side Effect

What Our Customers Say
Ready to Lead the Market with Confidence?

As global regulators like EFSA tighten restrictions on monacolin K—even at trace levels—traditional red yeast rice products are facing growing regulatory uncertainty.

ANKASCIN® 568 offers a proven, future-ready solution: no monacolin K, no statin-like side effects, and full compliance with current and emerging global standards.

In a nutraceutical world that demands innovation, safety, and scientific validation, ANKASCIN® 568 gives your brand the power to lead with confidence.

Free Sample Request

Contact Us
Contact Us